GSK plc 6-K, filed May 9, 2023
GSK plc (GSK)
6-K
2023-05-09
For: 2023-05-09
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on May 9, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Sir Jonathan Symonds
|
|||
|
b)
|
Position/status
|
Non-Executive
Chair
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31
¼ pence each
('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Release of 35,439 notional Ordinary Shares from the GSK
Non-Executive Director Share Allocation Arrangements prior to
termination of those arrangements, the withholding of 16,656
notional Ordinary Shares for tax and the final release of 18,782
Ordinary Shares representing the balance. These shares will be held
by Sir Jonathan Symonds until he retires from the
Board
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.556
|
18,782
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-05-04
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr Urs
Rohner
|
|||
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Release of 19,083 notional Ordinary Shares from the GSK
Non-Executive Director Share Allocation Arrangements prior to
termination of those arrangements, the withholding of 4,446
notional Ordinary Shares for tax and the final release of 14,637
Ordinary Shares representing the balance. These shares will be held
by Mr Rohner until he retires from the Board
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.556
|
14,637
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date of
the transaction
|
2023-05-04
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
9, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|